Trial Profile
A Phase 1 Expansion Cohort Evaluating the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Unresectable Melanoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions
- 31 Mar 2023 Status changed from active, no longer recruiting to completed.
- 05 Sep 2022 Planned End Date changed from 31 Dec 2019 to 31 Dec 2022.
- 05 Sep 2022 Status changed from recruiting to active, no longer recruiting.